European framework for tuberculosis control and elimination in countries with a low incidence

“…screening targeting all immigrants, irrespective of symptoms. For the purpose of this review we considered studies performing both radiological and microbiological tests to identify cases of active tuberculosis [12]. We excluded the following studies: 1) studies only reporting prevalence of latent tuberculosis infection; 2) studies only reporting tuberculosis cases in children (reported as such in the paper or younger than 16 yrs of age); 3) studies only identifying cases through passive case finding; 4) studies only reporting tuberculosis prevalence among migrants moving from areas of low incidence; 5) studies only reporting cases of multidrug-resistant tuberculosis; 6) studies only including migrants who had undergone screening prior to leaving the country of origin; and 7) studies only reporting tuberculosis incidence data among immigrants.…”

Section: Study Selectionmentioning

confidence: 99%

Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis

Arshad¹,

Bavan²,

Gajari³

et al. 2009

European Respiratory Journal

105

View full text Add to dashboard Cite

Although there is no evidence that imported tuberculosis increases the incidence of the disease in host countries, the rise in migration worldwide raises concerns regarding the adequacy of surveillance and control of immigrant-associated tuberculosis in low incidence countries. Assessing the performance of screening of immigrants for tuberculosis is key to rationalising control policies for the detection and management of immigrant-associated tuberculosis.We performed a systematic review and meta-analysis to determine the yield of active screening for tuberculosis among new immigrants at the point of entry.The yield for pulmonary tuberculosis was 3.5 cases per 1,000 screened (95% CI 2.9-4.1; I 2 594%); for refugees, asylum seekers and regular immigrants the estimates were 11.9 (95% CI 6.7-17.2; I 2 592%), 2.8 (95% CI 2.0-3.7; I 2 596%) and 2.7 (95% CI 2.0-3.4; I 2 581%), respectively.The yield estimates for immigrants from Europe, Africa and Asia were 2.4 (95% CI 1.3-3.4; I 2 551.5%), 6.5 (95% CI 3.2-10.0; I 2 562%) and 11.2 (95% CI 6.2-16.1; I 2 595%), respectively.These results provide useful data to inform the development of coherent policies and rational screening services for the detection of immigrant-associated tuberculosis.

show abstract

“…The historical summary of the Wolfheze workshops and their consensus documents with recommendations on TB control activities in the EU [21] highlights the ultimate target of TB elimination, defined as a TB incidence of less than one case per million population [22]. As it must be recognised, following current trends, Europe is unlikely to achieve elimination of the disease by the target date of 2050 [23,24], we urgently need new vaccines, as well as improved diagnostics [25,26] and new drugs [27][28][29].…”

Section: Introductionmentioning

confidence: 99%

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

Diel

Vandeputte²,

Vries

et al. 2013

European Respiratory Journal

157

131

View full text Add to dashboard Cite

Without better vaccines it is unlikely that tuberculosis (TB) will ever be eliminated. An investment of ,J560 million is considered necessary to develop a new, effective vaccine in the European Union (EU). However, less is known about the costs of TB disease in the EU. We performed a systematic review of literature and institutional websites addressing the 27 EU members to summarise cost data. We searched MEDLINE, EMBASE and Cochrane bibliographies for relevant articles.Combining direct and indirect costs, we arrived at an average per-TB case costs in the original EU-15 states plus Cyprus, Malta and Slovenia of J10 282 for drug-susceptible TB, J57 213 for multidrug resistant (MDR)-TB and J170 744 for extensively drug resistant (XDR)-TB. In the remaining new EU states, costs amounted to J3427 for drug-susceptible TB and J24 166 for MDR-TB/XDR-TB. For the 70 340 susceptible TB cases, 1488 MDR-TB and 136 XDR-TB cases notified in 2011 costs of J536 890 315 accumulated in 2012. In the same year, the 103 104 disability-adjusted life years caused by these cases, when stated in monetary terms, amounted to a total of J5 361 408 000.Thus, the resulting economic burden of TB in the EU clearly outweighs the cost of investing in more efficient vaccines against TB. @ERSpublications The economic burden of tuberculosis in the EU outweights the cost of investing in more efficient vaccines against tuberculosis

show abstract

European framework for tuberculosis control and elimination in countries with a low incidence

Cited by 261 publications

References 51 publications

Yield of tuberculosis contact investigation in a low-incidence country

Yield of tuberculosis contact investigation in a low-incidence country

Active screening at entry for tuberculosis among new immigrants: a systematic review and meta-analysis

Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation

Contact Info

Product

Resources

About